Noted This Week

Guardant Health laid off about 7% of its staff. The decision was made, the company said, to "better support both our near- and long-term growth as well as out path to profitability. This decision puts us in an even better position to deliver on the promise we made ten years ago to transform cancer care." The company makes the Guardant360 assay and blood tests to help inform treatment decisions, monitor treatment response, and detect recurrent/residual disease.

More Noted This Week, January 20–26   »